Global Tumor Necrosis Factor Inhibitor Market by Product Types (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and Biosimilars), Applications (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing S
The global tumor necrosis factor inhibitor market was valued at USD 40.3 billion in 2019 and is expected to reach USD 42.1 billion by 2026, expanding at a CAGR of around 3.6% during the forecast period, 2020 – 2026. The growth of the market is attributed to increasing prevalence of autoimmune diseases, technological advancements and rising healthcare expenditure. Tumor Necrosis Factor (TNF) is a cell signaling protein part of systemic inflammation and is a cytokine that is involved in acute phase reaction. TNF inhibitor is pharmaceutical drug used for suppressing physiological response to TNF which is part of the inflammation associated carcinogenesis. It is part of medication for autoimmune and immune-mediated disorders. The inhibitor is also used for treating rheumatoid arthritis, skin diseases, gastrointestinal diseases, and cancer.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing geriatric population highly prone to disease is driving the market growth.
- Growing awareness regarding autoimmune disorder and promising diagnostics is fueling the growth of the market.
- Side effects of the medication such as infection and bruises are expected to hamper the market growth
- Heavy investments in the market for extensive R&D is anticipated to foster the growth of the market.
- Global expansion of pharmaceutical and healthcare industries is expected to fuel the growth of the market in forecasted period.
Scope of the Report
The report on the global tumor necrosis factor inhibitor market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report. AttributesDetailsBase Year2019Historic Data2015–2018Forecast Period2020–2026Regional ScopeAsia Pacific, Europe, North America, the Middle East & Africa, and Latin AmericaReport CoverageCompany Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Global Tumor Necrosis Factor Inhibitor Segment Insights:
On the basis of product types, the market is divided into humira, enbrel, remicade, simponi/simponi aria, cimzia, and biosimilars. Humira has dominated the segment since past many years and is anticipated to retain its position in the market due to its patent exclusivity up to year 2023, later biosimilars are expected to take over the market and experience exponential growth due to new product launches and developments. Based on the applications, the market is branched into rheumatoid arthritis, psoriasis, psoriatic arthritis, crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and others. Rheumatoid arthritis has accounted for the highest market share due increasing incidence rates, rising awareness and high treatment rate and it is estimated to maintain peak position in the forecasted period with a substantial growth. In terms of distribution channel, the market is fragmented into hospital pharmacies, specialty pharmacies, and online pharmacies. Hospital pharmacies had accounted for largest share since past three years due to lowest proximity of purchase when prescribed by the physician. Online pharmacies are expected to capture market at a significant pace owing to its discount and promotional activities. On the basis of regions, the market is segmented into Asia Pacific, Europe, North America, Middle East & Africa, and Latin America. North America has the highest market share owing to its strong commercial use, favorable reimbursement conditions, growing awareness and presence of giant market players and availability of good infrastructural facilities, and higher disposable income among consumers.
Competitive Landscape:
Major companies in global tumor necrosis factor inhibitor market includes Merck & Co. Inc, Pfizer Inc, Novartis International AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc, and Janssen Biotech Inc. The market players are engaged in developing products using chemically stable compounds to avoid side effects and to amplify their market share and gain traction in global marketplace. The companies are engaging in strategic acquisitions such as product launches, R&D, agreements, and collaborations to gain market share. On November 2019, Pfizer Inc announced the news of its drug ABRILADA (adalimumab-afzb) which had got its approval from United States Food and Drug Administration (FDA) as a biosimilar to Humira for treating patients suffering from TNF. The company is expected to launch the product by 2023 post entering into agreement with AbbVie Inc. It is expected to be potential solution for saving cost incurred in healthcare expenditure of patients. FDA reported no clinically meaningful differences in efficacy, safety or immunogenicity as compared to the reference product under various testing conditions.
The global tumor necrosis factor inhibitor market has been segmented on the basis of
Product Types
- Humira
- Enbrel
- Remicade
- Simponi/Simponi Aria
- Cimzia
- Biosimilars
Applications
- Rheumatoid Arthritis
- Psoriasis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis,
- Hidradenitis Suppurativa
- Others
Distribution Channels
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
Regions
- Asia Pacific
- Europe
- North America
- Middle East & Africa
- Latin America